Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia
- Bon Secours Richmond Community Hospital — Richmond, Virginia
- Bon Secours Saint Mary's Hospital — Richmond, Virginia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine o…
Sponsor: NRG Oncology
NCT ID: NCT07097142
Sites in Virginia: - Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia
- Bon Secours Saint Mary's Hospital — Richmond, Virginia
- Bon Secours Cancer Institute at Reynolds Crossing — Richmond, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in c…
Sponsor: Eli Lilly and Company
NCT ID: NCT07218380
Sites in Virginia: - USO - Virginia Oncology Associates — Norfolk, Virginia
Phase 3 Recruiting Industry
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Sponsor: Ferring Pharmaceuticals
NCT ID: NCT06510374
Sites in Virginia: - Urology of Virginia — Virginia Beach, Virginia
Phase 2, Phase 3 Recruiting Industry
This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizu…
Sponsor: Daiichi Sankyo
NCT ID: NCT07129993
Sites in Virginia: - Research Site — Charlottesville, Virginia
- Research Site — Norfolk, Virginia
Phase 2, Phase 3 Recruiting Industry
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07106762
Sites in Virginia: - University of Virginia Health System — Charlottesville, Virginia
- Local Institution - 0188 — Norfolk, Virginia
Phase 2 Recruiting Industry
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that …
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04879329
Sites in Virginia: - Inova Schar Cancer Institute — Fairfax, Virginia
Phase 2 Recruiting NIH
This phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer. Standard of care therapy inc…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061964
Sites in Virginia: - VCU Massey Cancer Center at Stony Point — Richmond, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 2 Recruiting NIH
This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunothe…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06770582
Sites in Virginia: - Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia
- Bon Secours Saint Mary's Hospital — Richmond, Virginia
- Bon Secours Cancer Institute at Reynolds Crossing — Richmond, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 2 Recruiting Industry
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Sponsor: CG Oncology, Inc.
NCT ID: NCT06567743
Sites in Virginia: - Urology of Virginia — Virginia Beach, Virginia
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establis…
Sponsor: enGene, Inc.
NCT ID: NCT04752722
Sites in Virginia: - University of Virginia Comprehensive Cancer Center — Charlottesville, Virginia
Phase 2 Recruiting Industry
TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101…
Sponsor: Protara Therapeutics
NCT ID: NCT05951179
Sites in Virginia: - Virginia Urology — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissue…
Sponsor: Pfizer
NCT ID: NCT07421700
Sites in Virginia: - Oncology & Hematology Associates of Southwest Virginia, Inc.,DBA Blue Ridge Cancer Care — Blacksburg, Virginia
- Virginia Cancer Specialists, PC — Fairfax, Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc.,DBA Blue Ridge Cancer Care — Low Moor, Virginia
- Virginia Oncology Associates — Norfolk, Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc.,DBA Blue Ridge Cancer Care — Roanoke, Virginia
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 2 Recruiting Industry
Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06833073
Sites in Virginia: - Urology of Virginia ( Site 0125) — Virginia Beach, Virginia
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 2 Recruiting Industry
This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") (with or without resected papillary disease (Ta,…
Sponsor: Theralase® Technologies Inc.
NCT ID: NCT03945162
Sites in Virginia: - Site 02-009 - Virginia Urology — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle invasive bladder cancer (NMIBC) who have not received Bacillus Calmette-Guérin and …
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06800963
Sites in Virginia: - Potamac Urology Center — Alexandria, Virginia
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Virginia: - NEXT Oncology Virginia — Fairfax, Virginia
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Virginia: - NEXT Oncology - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1 Recruiting Industry
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-d…
Sponsor: IDEAYA Biosciences
NCT ID: NCT07277413
Sites in Virginia: - NEXT Oncology Virginia — Fairfax, Virginia
Phase 1 Recruiting Industry
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as m…
Sponsor: OncoNano Medicine, Inc.
NCT ID: NCT06022029
Sites in Virginia: - Virginia Cancer Specialists, PC — Fairfax, Virginia
Phase 1 Recruiting Industry
The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligib…
Sponsor: EvolveImmune United, Inc
NCT ID: NCT07217171
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Virginia: - Chesapeake Regional Medical Center — Chesapeake, Virginia
- Augusta Health Center for Cancer and Blood Disorders — Fishersville, Virginia
- Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
- Bon Secours Westchester Emergency Center — Midlothian, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia